---
schema_version: "secwatch.filing_event.v1"
accession: "0001636651-25-000011"
form_type: "8-K"
ticker: "OVID"
cik: "0001636651"
company_name: "Ovid Therapeutics Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:15:02.344678+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ovid Therapeutics announces CEO succession, Q3 2025 loss, and pipeline progress

## Summary
- Meg Alexander appointed CEO effective Jan 1, 2026; Jeremy Levin to become Executive Chairman.
- Q3 2025 net loss $12.2M ($0.17/sh) vs $14.0M ($0.20) YoY; cash $25.6M at Sep 30.
- Completed $81M private placement (up to $175M); cash runway extended into 2H 2028.
- OV329 Phase 1 positive; Phase 2a in drug-resistant epilepsies planned Q2 2026.
- OV350 IV data expected Q4 2025; OV4071 oral KCC2 activator to enter clinic Q2 2026.

## SEC filing metadata
- accession: 0001636651-25-000011
- form_type: 8-K
- ticker: OVID
- cik: 0001636651
- company_name: Ovid Therapeutics Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636651/000163665125000011/0001636651-25-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636651/000163665125000011/ovid-20251112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001636651-25-000011
- JSON: https://secwatch.observer/filing/0001636651-25-000011.json
- Plain text: https://secwatch.observer/filing/0001636651-25-000011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.